Your browser is no longer supported. Please, upgrade your browser.
Settings
IKNA [NASD]
Ikena Oncology, Inc.
Index- P/E- EPS (ttm)-1.28 Insider Own0.10% Shs Outstand32.28M Perf Week16.28%
Market Cap827.66M Forward P/E- EPS next Y-1.47 Insider Trans0.00% Shs Float9.77M Perf Month15.39%
Income-44.30M PEG- EPS next Q-0.68 Inst Own15.40% Short Float5.87% Perf Quarter-
Sales9.20M P/S89.96 EPS this Y-163.20% Inst Trans- Short Ratio1.51 Perf Half Y-
Book/sh- P/B- EPS next Y-4.30% ROA- Target Price28.50 Perf Year-
Cash/sh5.03 P/C5.09 EPS next 5Y- ROE- 52W Range14.16 - 37.61 Perf YTD-19.88%
Dividend- P/FCF- EPS past 5Y- ROI44.00% 52W High-31.83% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low81.07% ATR3.33
Employees33 Current Ratio5.90 Sales Q/Q-97.70% Oper. Margin- RSI (14)- Volatility8.88% 15.75%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.51 Prev Close24.62
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume379.79K Price25.64
Recom1.50 SMA2026.31% SMA5016.97% SMA20016.97% Volume197,370 Change4.14%
May-05-21Resumed Credit Suisse Outperform $30
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-20-21Initiated William Blair Outperform
Apr-20-21Initiated Jefferies Buy
Apr-20-21Initiated Credit Suisse Outperform $30
Apr-15-21 07:00AM  
Mar-30-21 04:05PM  
Mar-25-21 08:55PM  
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.